Aptevo Therapeutics (APVO) Other Non-Current Assets (2015 - 2022)
Aptevo Therapeutics (APVO) posted Other Non-Current Assets of $427000.0 for Q3 2022, down 21.79% sequentially from $546000.0 in Q2 2022, and down 42.76% YoY from $746000.0 in Q3 2021.
Aptevo Therapeutics (APVO) Other Non-Current Assets (2015 - 2022) Analysis & Trends
Aptevo Therapeutics has reported Other Non-Current Assets for 8 years, with the latest figure at $427000.0 in Q3 2022.
- Quarterly Other Non-Current Assets fell 42.76% year-over-year to $427000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $427000.0 (down 42.76% YoY) and the FY2021 annual result came in at $68000.0, down 90.88% from the prior year.
- Other Non-Current Assets declined to $427000.0 in Q3 2022 per APVO's latest filing, from $546000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $12.4 million in Q2 2018 and troughed at $25000.0 in Q3 2018.
- A 5-year average of $3.0 million and a median of $746000.0 in 2020 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2018 and 2019: Other Non-Current Assets slumped 99.23% in 2018, then jumped 29892.0% in 2019.
- Over 5 years, Other Non-Current Assets stood at $7.4 million in 2018, then climbed by 0.67% to $7.5 million in 2019, then sank by 90.05% to $746000.0 in 2020, then tumbled by 90.88% to $68000.0 in 2021, then jumped by 527.94% to $427000.0 in 2022.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $427000.0, $546000.0, and $68000.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 427,000.00 |
| Jun 30, 2022 | 546,000.00 |
| Mar 31, 2022 | 68,000.00 |
| Dec 31, 2021 | 68,000.00 |
| Sep 30, 2021 | 746,000.00 |
| Jun 30, 2021 | 746,000.00 |
| Mar 31, 2021 | 746,000.00 |
| Dec 31, 2020 | 746,000.00 |
| Sep 30, 2020 | 757,000.00 |
| Jun 30, 2020 | 693,000.00 |
| Mar 31, 2020 | 2.53 Mn |
| Dec 31, 2019 | 7.50 Mn |
| Sep 30, 2019 | 7.50 Mn |
| Jun 30, 2019 | 1.25 Mn |
| Mar 31, 2019 | 1.25 Mn |
| Dec 31, 2018 | 7.45 Mn |
| Sep 30, 2018 | 25,000.00 |
| Jun 30, 2018 | 12.45 Mn |
| Mar 31, 2018 | 11.24 Mn |
| Dec 31, 2017 | 10.00 Mn |